Eli Lilly and Company $LLY Shares Purchased by Burling Wealth Partners LLC

Burling Wealth Partners LLC grew its position in Eli Lilly and Company (NYSE:LLY) by 6.1% in the 4th quarter, Holdings Channel.com reports. The firm owned 13,281 shares of the company’s stock after buying an additional 758 shares during the period. Eli Lilly and Company makes up approximately 2.2% of Burling Wealth Partners LLC’s investment portfolio, making the stock its 13th largest position. Burling Wealth Partners LLC’s holdings in Eli Lilly and Company were worth $14,273,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. 10Elms LLP grew its position in Eli Lilly and Company by 33.3% in the 3rd quarter. 10Elms LLP now owns 40 shares of the company’s stock worth $31,000 after purchasing an additional 10 shares during the last quarter. M.E. Allison & CO. Inc. grew its position in Eli Lilly and Company by 0.7% in the 4th quarter. M.E. Allison & CO. Inc. now owns 1,477 shares of the company’s stock worth $1,587,000 after purchasing an additional 10 shares during the last quarter. Tanager Wealth Management LLP grew its position in Eli Lilly and Company by 2.6% in the 4th quarter. Tanager Wealth Management LLP now owns 395 shares of the company’s stock worth $424,000 after purchasing an additional 10 shares during the last quarter. Morey & Quinn Wealth Partners LLC grew its position in Eli Lilly and Company by 1.5% in the 4th quarter. Morey & Quinn Wealth Partners LLC now owns 661 shares of the company’s stock worth $710,000 after purchasing an additional 10 shares during the last quarter. Finally, Wealthspan Partners LLC grew its position in Eli Lilly and Company by 0.5% in the 4th quarter. Wealthspan Partners LLC now owns 2,110 shares of the company’s stock worth $2,268,000 after purchasing an additional 10 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Scotiabank reiterated an “outperform” rating and issued a $1,300.00 price objective on shares of Eli Lilly and Company in a report on Thursday, February 5th. Jefferies Financial Group set a $1,300.00 target price on Eli Lilly and Company and gave the stock a “buy” rating in a report on Friday, March 13th. CICC Research upped their target price on Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 11th. Sanford C. Bernstein restated an “outperform” rating on shares of Eli Lilly and Company in a research report on Tuesday, March 10th. Finally, Cantor Fitzgerald upped their target price on Eli Lilly and Company from $1,205.00 to $1,230.00 and gave the stock an “overweight” rating in a research report on Friday, May 1st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $1,218.33.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly said results from its oral GLP-1 program are encouraging, supporting the outlook for a future pill that could broaden the company’s obesity and diabetes franchise. From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook
• Positive Sentiment: The company expanded its pipeline with the acquisition of Engage Biologics for up to $202 million, adding non-viral DNA delivery technology and strengthening its genetic medicine ambitions. Eli Lilly Buys Engage Biologics for Up to $202 Million
• Positive Sentiment: Lilly also expanded access to its TuneLab AI/ML drug discovery platform through a partnership with Collaborative Drug Discovery, reinforcing its push to use artificial intelligence to accelerate R&D. Collaborative Drug Discovery Partners with Lilly TuneLab to Make Lilly AI/ML Models Available in CDD Vault
• Positive Sentiment: Analysts and industry coverage highlighted Lilly’s strong earnings call and its high R&D performance, which support the view that the company’s growth trajectory remains strong. Eli Lilly Earnings Call Signals High-Growth Trajectory
• Neutral Sentiment: Lilly completed a large $8.9 billion debt offering, which gives the company additional financial flexibility but also increases leverage. Eli Lilly Raises $8.9 Billion in Debt Offering
• Neutral Sentiment: A lawsuit alleging more than $200 million in Trulicity rebate fraud is a separate risk factor, though it appears to be more about recovering losses than a direct operational setback. Eli Lilly accuses church bishops, businessmen of fraud in Trulicity drug rebate scheme

Eli Lilly and Company Trading Down 0.5%

Eli Lilly and Company stock opened at $1,016.05 on Thursday. The company has a 50 day moving average price of $940.69 and a 200 day moving average price of $1,002.07. The firm has a market capitalization of $956.85 billion, a price-to-earnings ratio of 36.09, a P/E/G ratio of 1.11 and a beta of 0.48. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The company had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The company’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same quarter last year, the business posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Research analysts forecast that Eli Lilly and Company will post 35.82 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. Eli Lilly and Company’s payout ratio is currently 24.58%.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.